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Abstract  
 
Colonization and infection by resistant strains of 
Staphylococcus aureus are being reported in 
epidemic proportions.  The goal of this study was to 
determine the local prevalence of methicillin-resistant 
Staphylococcus aureus (MRSA) colonization in 
pregnant women in southern Nevada and how it 
correlates with colonization and infection of their 
neonates.  Signed consent was obtained, and a brief 
questionnaire was administered by the medical staff 
to each pregnant woman to collect demographic data 
and pertinent medical, family and social history.  
Nasal and vaginal specimens were obtained from 
pregnant women at ≥35 weeks gestation, and nasal 
and umbilicus specimens were obtained from their 
newborns.  Specimens were cultured onto two 
selective media for S. aureus and MRSA.  Potential 
MRSA isolates were further evaluated for 
susceptibility to antibiotics.  Specimens from 307 
pregnant women and 174 neonates were collected, 
resulting in 172 mother-neonate paired specimens.  A 
total of 278 questionnaires were received from study 
participants.  MRSA prevalence in pregnant women 
was 1.0% and 0.3% for nasal and vaginal specimens, 
respectively.  The MRSA prevalence in neonates was 
0% and 0.6% for nasal and umbilical specimens, 
respectively.  Four different antimicrobial 
susceptibility profiles were observed among the 
MRSA isolates.  The results did not show 
transmission of MRSA from pregnant women to their 
newborns, or infections of newborns with MRSA.  It 
is expected that the results of this study will inform 
future decisions on surveillance, treatment and 
prevention of MRSA infections in Nevada. 
 
Key words antimicrobial susceptibility, colonization, 
methicillin-resistant Staphylococcus aureus, MRSA 
 
Introduction 
 
Colonization and infection by community-associated 
resistant strains of Staphylococcus aureus are being 
reported in epidemic proportions in many areas of the 
United States and around the world (Creech II, 
Kernodle, Alsentzer, Wilson, & Edwards, 2005; Faria 
et al., 2005; Mulvey et al., 2005; Taiwo et al., 2005).  
Although more frequently associated with skin and 
soft tissue infections, community-associated 
methicillin-resistant Staphylococcus aureus (CA-
MRSA) has been implicated in invasive infections in 
children, with wide geographical diversity in rates of 
colonization and infection (Kaplan et al., 2005; 
Ochoa, Mohr, Wanger, Murphy, & Heresi, 2005; 
Purcell & Fergie, 2005).  Studies have shown that 
MRSA is a common bacterium in the Neonatal 
Intensive Care Unit (NICU) (Chen, Huard, Della-
Latta, & Saiman, 2006; Khoury, Jones, Grim, Dunne, 
& Fraser, 2005).  MRSA is recognized as a cause of 
infection among newborns in the NICU, and the 
existence of MRSA colonization in pregnant women 
has potential health implications for their neonates 
(Beigi & Hanrahan, 2007).  A recent study identified 
MRSA colonization in prenatal vaginal cultures and 
raised questions with regards to pregnant women and 
their infants’ wellbeing (Chen, Huard, Della-Latta, & 
Saiman, 2006).  This may be due to the fact that 
persons colonized with MRSA are usually at a higher 
risk for infections and possibly transmit the 
bacterium to other family members (Chen, Huard, 
Della-Latta, & Saiman, 2006).  Various studies have 
addressed the problem of MRSA in the NICU (Chen, 
Huard, Della-Latta, & Saiman, 2006; Chuang et al., 
2004; Khoury, Jones, Grim, Dunne, & Fraser, 2005), 
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but there are limited data regarding the relationship 
between maternal vaginal colonization and the rate of 
infection found in their neonates.  In addition, no 
consensus guidelines exist regarding the appropriate 
evaluation and treatment of previously healthy term 
and late-preterm neonates with community-
associated S. aureus infections, especially those 
caused by CA-MRSA isolates (Fortunov, Hulten, 
Hammerman, Mason, & Kaplan, 2007). 
 
The increasing rate of MRSA cases has led many 
clinicians to utilize newer staphylococcal 
antimicrobial agents as first-line empiric therapy.  
While some studies report equal efficacy or 
superiority of linezolid to vancomycin in treatment of 
MRSA (Sharpe, Shively, & Polk Jr., 2005; Shorr, 
Kunkel, & Kollef, 2005), there are reports of 
increasing clindamycin and rifampicin resistance 
among MRSA and of unstable vancomycin 
heteroresistance among clinical isolates of MRSA 
(Braun, Craft, Williams, Tuamokumo, & Ottolini, 
2005; Plipat, Livni, Bertram, & Thompson, 2005; 
Tosun et al., 2005).  The two most important 
considerations in choosing empiric antibiotic therapy 
are the knowledge of the most likely pathogen and 
the most likely active antimicrobial agent.  With the 
increasing prevalence of MRSA, the large 
geographical diversity in colonization and infection 
rates, and the presence of increasing resistance to 
available therapies, clinicians should be aware of 
their local resistance rates.  One method of gaining 
this knowledge is to maintain surveillance programs 
(both inpatient and outpatient) in order to identify 
local colonization rates and their relationship to 
clinical infections, as well as antibiotic resistance 
patterns.  The goal of this study was to determine the 
prevalence of MRSA colonization in pregnant 
women and its potential association with MRSA 
colonization and infection in newborns delivered at 
the University Medical Center (UMC) in Las Vegas, 
Nevada.   
 
Materials and Methods 
Study Procedures 
Nares and vaginal swabs were collected from 307 
pregnant women at ≥35 weeks gestation presenting 
for care or delivery at three sites:  Women’s Center, 
Patient Care Center, and Birthing Center of the 
University Medical Center in Las Vegas, Nevada.  
Signed consent was obtained, and a brief 
questionnaire was administered by the medical staff 
to each pregnant woman to collect demographic data 
and pertinent medical, family and social history.  
Nares and umbilical swabs were collected from 174 
neonates prior to discharge from the hospital.  
Specimens were cultured onto two selective media 
for the isolation of S. aureus and MRSA.  The 
VITEK
®
 2 Compact (bioMérieux, Durham, NC) and 
the Kirby-Bauer disc diffusion method were used to 
characterize isolates based on their susceptibility to 
antimicrobial agents.  Data were analyzed statistically 
to determine MRSA prevalence rates and to provide 
descriptive summary statistics across all collected 
variables for each study participant. 
 
Test Organisms and Culture Media 
Seven bacterial reference strains obtained from the 
American Type Culture Collection (Manassas, VA) 
were used in this study:  Escherichia coli ATCC 
25922, S. aureus ATCC 29213 and ATCC 25923 
(methicillin-sensitive strains), S. aureus ATCC 43300 
(a MRSA strain), S. epidermidis ATCC 12228, S. 
saprophyticus ATCC 15305, and Proteus mirabilis 
ATCC 12453.  All media were obtained from BD 
Diagnostics, Sparks, MD, and consisted of BBL™ 
CHROMagar™ Staph aureus, BBL™ 
CHROMagar™ MRSA, BBL™ Oxacillin Screen 
Agar (OSA), BBL™ Mueller Hinton II agar, Difco™ 
Tryptic Soy Agar (TSA), and Trypticase™ Soy Agar 
with 5% Sheep Blood (TSAB).  All cultures were 
incubated at 35°C for 24–48 hours. 
 
Specimen Collection and Processing  
Nares specimens were collected by medical staff with 
a dry, sterile swab (BBL CultureSwab; BD 
Diagnostics) which was inserted into each nostril of 
each subject, rotated for 5 seconds, and placed into a 
tube of liquid Stuart transport medium (BD 
Diagnostic).  Vaginal specimens were collected at the 
same time specimens were collected for Group B 
streptococcus screening by swabbing the vaginal 
vault using a dry, sterile swab.  Umbilical specimens 
were collected 24 hours after birth and prior to 
discharge from the hospital by swabbing the 
umbilical stump.  Specimens were refrigerated, 
transported to the laboratory within 48 hours, and 
processed immediately upon arrival.  Nares 
specimens were streaked for isolation onto BBL 
CHROMagar™ Staph aureus and BBL 
CHROMagar™ MRSA; all agar plate media were 
incubated in ambient atmosphere at 35°C for 24 
hours (Figure 1).  Media performance characteristics 
were obtained from the manufacturer’s package 
inserts.  Mauve to orange/mauve colonies produced 
on CHROMagar™ Staph aureus medium were 
identified as S. aureus isolates.  Smooth, moderately 
sized mauve colonies which appeared on 
CHROMagar™ MRSA medium at 24 hours were 
interpreted as MRSA isolates.  CHROMagar™ 
MRSA plates without typical MRSA colonies were 
incubated for an additional 24 hours.  Mauve colonies 
appearing at 48 hours and those with atypical growth 
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Figure 1  Flow chart illustrating the experimental design for nares sites using CHROMagar Staph aureus and 
CHROMagar MRSA (TSAB = 5% sheep blood agar; coag. = coagulase). 
 
 
 
rates or colony morphology were subcultured to 
TSAB, incubated in ambient atmosphere at 35°C for 
24 hours, then tested for coagulase activity (ASI 
Staphslide Latex Test; Arlington Scientific, Inc., 
Springville, UT) according to the manufacturer’s 
instructions. 
Umbilical and vaginal specimens were streaked for 
isolation onto CHROMagar™ Staph aureus and 
incubated as previously described.  S. aureus isolates 
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Figure 2  Flow chart illustrating the experimental design for sites other than nares using CHROMagar Staph aureus 
(TSAB = 5% sheep blood agar; OSA = Oxacillin Screen Agar; MSSA = methicillin sensitive Staphylococcus 
aureus). 
 
 
were sub-cultured onto TSAB and incubated in 
ambient atmosphere at 35°C for 24 hours.  The 
resulting colonies were tested for oxacillin 
susceptibility using OSA following the 
manufacturer’s guidelines (Figure 2).  All 
presumptive MRSA isolates were subcultured onto 
TSAB, tested for coagulase activity, and were stored 
at –70°C. 
 
Antimicrobial Susceptibility Testing 
Antimicrobial susceptibility testing was performed 
with the VITEK® 2 Compact System (bioMérieux, 
Durham, NC) using the AST-GP67 card; 
antimicrobials and concentrations are shown in Table 
1. 
MRSA isolates and control culture S. aureus ATCC 
25923 were subcultured onto TSA and incubated for 
18-24 hours in ambient atmosphere at 35°C.  A 
suspension of each isolate, at an optical density of 
0.5-0.63 McFarland standard, was loaded onto an 
AST-GP67 card and processed in the VITEK 2 
Compact according to the manufacturer’s protocols.  
Susceptibility profiles were stored electronically in 
the system and evaluated.  For comparison purposes, 
isolates were also tested using the Kirby-Bauer disc 
diffusion method on Mueller Hinton medium 
according to Clinical and Laboratory Standards 
Institute (CLSI; Wayne, PA) standards; 
antimicrobials and concentrations are shown in Table 
1.  All antimicrobial agents were obtained from 
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Table 1  Agents used in antimicrobial susceptibility testing of MRSA isolates (N/A = not applicable; CC or CM = 
Clindamycin; E = Erythromycin). 
 
VITEK
®
 2 Compact Disc Diffusion Method 
Antimicrobial Agent 
Concentration 
( g/ml) 
Antimicrobial Agent 
Concentration 
( g) 
Benzylpenicillin 0.125, 0.25, 1, 2, 8, 64   
Beta-lactamase N/A   
Cefoxitin screen 6   
Ciprofloxacin 1, 2, 4   
Clindamycin 0.5, 1, 2 Clindamycin 2 
Erythromycin 0.25, 0.5, 2 Erythromycin 15 
Gentamicin 8, 16, 64 Gentamicin 10 
Inducible Clindamycin 
resistance 
CM 0.5;  
CM/E 0.25/0.5 
Inducible Clindamycin 
resistance (CC/E) 
2/15 
Levofloxacin 0.25, 2, 8 Levofloxacin 5 
Linezolid 0.5, 1, 2 Linezolid 30 
Moxifloxacin 0.25, 2, 8   
Nitrofurantoin 16, 32, 64   
Oxacillin 0.5, 1, 2   
Quinupristin/Dalfopristin 0.25, 0.5, 2   
Rifampicin 0.25, 0.5, 2 Rifampin 5 
Tetracycline 0.5, 1, 2 Tetracycline 30 
Tigecycline 0.25, 0.5, 1   
Trimethoprim/ 
Sulfamethoxazole 
2/38, 8/152, 16/304 
Trimethoprim/ 
Sulfamethoxazole 
1.25/23.75 
Vancomycin 1, 2, 4, 8, 16 Vancomycin 30 
 1 
 
 
Becton Dickinson.  Organisms included in testing for 
quality control purposes were S. aureus ATCC 25923 
and E. coli ATCC 25922.  Presumptive MRSA 
isolates were subcultured onto TSA and incubated for 
24 hours as described above.  Each bacterial 
suspension was prepared according to the 
antimicrobial agent manufacturer’s instructions by 
inoculating 5 ml of Bacto™ Tryptic Soy Broth (BD 
Diagnostics) with a few isolated colonies and the 
suspension diluted as needed to obtain turbidity 
equivalent to a 0.5 McFarland standard.  Within 15 
minutes of preparation, a sterile cotton swab was 
dipped into the suspension; excess liquid was 
expressed from the swab.  The agar surface was 
inoculated three times, rotating the plate 60° each 
time, then sweeping the swab around the outer rim of 
the agar.  The plates were allowed to dry at room 
temperature for 3–5 minutes before applying the 
discs.  Four and five discs, respectively, were placed 
manually onto each plate with sterile forceps and 
pressed firmly onto the surface.  To detect inducible 
clindamycin resistance, double disc diffusion testing 
(D test) was performed by placing the clindamycin 
and erythromycin discs 15 mm apart (center to 
center); all other discs were placed 30 mm apart.  
Plates were incubated aerobically at 35°C and zone 
diameters were measured after 16-18 hours of 
incubation; oxacillin disc zone diameters were 
measured at 24 hours.  Zone diameters were 
measured to the nearest millimeter and results were 
recorded as susceptible, intermediate, or resistant 
based on interpretive criteria provided by BD 
Diagnostics. 
 
Strain Typing 
Strain typing of MRSA isolates was performed using 
the DiversiLab
®
 System (bioMérieux, Inc.) according 
to manufacturer’s instructions.  Briefly, a 10 µl 
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loopful of cells was harvested from a 24 hour culture 
of each isolate grown on TSAB, and the DNA was 
extracted using the UltraClean™ Microbial DNA 
Isolation Kit (MO BIO Laboratories, Inc., Carlsbad, 
CA).  Genomic DNA concentration was measured 
spectrophotometrically and normalized prior to 
performing repetitive polymerase chain reaction (rep-
PCR) amplification.  Rep-PCR amplification was 
performed with the DiversiLab
®
 Staphylococcus 
Fingerprinting Kit in a GeneAmp
®
 PCR System 2400 
(Applied Biosystems, Foster City, CA) following the 
DiversiLab
®
 protocol.  The PCR product was loaded 
onto the DiversiLab
®
 LabChip and analyzed 
according to the manufacturer’s instructions.  Strain 
profiles were compared to isolates in the bioMérieux 
database with the DiversiLab
®
 software.  Isolates 
were grouped according to the closest match from the 
bioMérieux database’s isolates showing 90% 
similarity.  Additional review of the virtual gel 
images, graph overlays and similarity matrix were 
performed for samples showing similarities to two 
different strain types. 
 
Statistical Methods and Analyses 
Based on a yearly total of 5,000 births at UMC and a 
5% margin of error, it was estimated through power 
analysis that 360 participants would be needed to 
provide a population MRSA colonization prevalence 
rate with 95% confidence.  Prevalence of MRSA and 
S. aureus colonization were determined for mothers 
and newborns, along with strain type and 
antimicrobial susceptibility data.  Further, descriptive 
statistics for both quantitative and qualitative 
variables were calculated and summarized.  All 
statistics were calculated using SPSS version 17.0, 
SAS version 9.2, and NCSS/PASS 2004. 
 
Results  
Specimen Collection and Analysis 
Specimens from a total of 307 pregnant women (i.e., 
307 vaginal specimens and 307 nasal specimens) and 
174 neonates (i.e., 174 umbilical specimens and 174 
nasal specimens) were collected.  From these 
specimens, a total of 172 mother-neonate pairs were 
obtained.  The prevalence of MRSA in pregnant 
women was 1.0% and 0.3% for nares and vaginal 
specimens, respectively.  In neonates, MRSA 
colonization prevalence was 0% and 0.6% for nares 
and umbilicus specimens, respectively.  The 
prevalence of methicillin susceptible Staphylococcus 
aureus (MSSA) in pregnant women was 16.0% and 
5.2% for nares and vaginal specimens, respectively.  
The prevalence of MSSA in neonates was 0.6% and 
1.7% for nares and umbilicus specimens, 
respectively. 
 
Antimicrobial Susceptibility Testing 
Antimicrobial agent susceptibility results obtained 
with the VITEK 2 Compact for MRSA positive 
specimens are shown in Table 2.  Three different 
susceptibility profiles were obtained among the five 
MRSA positive isolates.  All five isolates were 
resistant to benzylpenicillin and oxacillin, four were 
resistant to erythromycin, and three isolates were 
resistant to ciprofloxacin and showed intermediate 
resistance to levofloxacin.   
 
Antimicrobial agent susceptibility results obtained 
with the Kirby-Bauer disc diffusion method for 
MRSA positive specimens confirmed data obtained 
with the VITEK 2 Compact, with the exception that 
isolates showing intermediate levofloxacin resistance 
with the VITEK 2 Compact were determined to be 
resistant with the Kirby-Bauer method (Table 3). 
 
Strain Typing 
No identical matches were obtained between the 
MRSA isolates in this study and the MRSA strains in 
the bioMérieux DiversiLab
®
 System database.  Three 
isolates with identical antimicrobial agent 
susceptibility profiles all were identified as being 
most closely related to the Iberian MRSA strain 
(95.4% to 97.6% similarity).  However, similarity to 
Brazilian (94.6% to 97.0%) and USA 700 (95.3% to 
95.8%) strains was also observed (data not shown). 
 
Questionnaire Data 
A total of 278 questionnaires were received with the 
307 specimens from pregnant women.  The number 
of respondents between categories varied due to 
incomplete or missing information obtained for some 
questions.  Basic summary statistics from the 
questionnaire responses from pregnant women 
showed a median age of 26 years of age (N = 243; 
Table 4). 
 
The majority of the pregnant women that participated 
in the study were of Hispanic ethnicity (80.3%), 
followed by Caucasian (8.4%) and African American 
(7.3%; N=274; Table 4).  The medical history of 
pregnant women revealed that 18 of 278 (6.5%) had 
Chlamydia and 28 of 278 (10.1%) had an abnormal 
PAP smear result in the past year (Table 5).  Three 
participants reported a previous Staphylococcus 
infection and were treated with antibiotics. 
 
Analysis of the questionnaire data from participants 
colonized by MRSA showed that the age of pregnant 
women ranged between 22.5 and 34.3, and that three 
were of Hispanic ethnicity and one was African 
American (Table 6).  Potential risk factors 
documented for these pregnant women included 
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Table 2  Antimicrobial agent susceptibility results obtained with the VITEK 2 Compact for MRSA positive 
specimens.  S. aureus ATCC 25923 was used as QC organism.  Antimicrobial agent susceptibility (Minimum 
Inhibitory Concentration) was determined with the CLSI M100-S16 (2006) Interpretation Guidelines (S = 
susceptible; I = intermediate; R = resistant; + represents positive; - represents negative). 
 
Antimicrobial Agent Conc. ( g/ml) 
MRSA Positive Specimen 
73MN 207MV 241MN 248MN 377BU 
Benzylpenicillin 0.125, 0.25, 1, 2, 8, 64 R R R R R 
Beta-lactamase N/A + + + + + 
Cefoxitin screen 6 + + + + + 
Ciprofloxacin 1, 2, 4 R R S S R 
Clindamycin 0.5, 1, 2 S S S S S 
Erythromycin 0.25, 0.5, 2 R R S R R 
Gentamicin 8, 16, 64 S S S S S 
Inducible Clindamycin 
resistance 
CM 0.5;  
CM/E 0.25/0.5 
- - - - - 
Levofloxacin 0.25, 2, 8 I I S S I 
Linezolid 0.5, 1, 2 S S S S S 
Moxifloxacin 0.25, 2, 8 S S S S S 
Nitrofurantoin 16, 32, 64 S S S S S 
Oxacillin 0.5, 1, 2 R R R R R 
Quinupristin/Dalfopristin 0.25, 0.5, 2 S S S S S 
Rifampicin 0.25, 0.5, 2 S S S S S 
Tetracycline 0.5, 1, 2 S S S S S 
Tigecycline 0.25, 0.5, 1 S S S S S 
Trimethoprim/ 
Sulfamethoxazole 
2/38, 8/152, 16/304 S S S S S 
Vancomycin 1, 2, 4, 8, 16 S S S S S 
 1 
Table 3  Antimicrobial agent susceptibility results obtained with the Kirby-Bauer disc diffusion method for MRSA 
positive specimens.  E. coli ATCC 25922 and S. aureus ATCC 25923 were used as QC organisms.  Antimicrobial 
agent susceptibility was determined with the Zone Diameter for Staphylococcus spp. Interpretive Standards (S = 
susceptible; R = resistant; - represents negative result; CC = Clindamycin; E = Erythromycin). 
 
Antimicrobial Agent 
Conc. 
( g) 
MRSA Positive Specimen 
73MN 207MV 241MN 248MN 377BU 
Clindamycin 2 S S S S S 
Erythromycin 15 R R S R R 
Gentamicin 10 S S S S S 
Inducible Clindamycin 
resistance (CC/E) 
2/15 - - - - - 
Levofloxacin 5 R R S S R 
Linezolid 30 S S S S S 
Rifampin 5 S S S S S 
Tetracycline 30 S S S S S 
Trimethoprim/Sulfamethoxazole 1.25/23.75 S S S S S 
Vancomycin 30 S S S S S 
 1 
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Table 4  Demographics from pregnant women and their neonates born at University Medical Center (S.D. = 
standard deviation). 
 
Mother’s Age (yrs) 
N Mean (yrs.) S.D. Minimum Maximum 
243 26.0 6.18 14.8 42.0 
Race/Ethnicity of Mother (N = 274) 
Race Frequency Percent 
Hispanic 220 80.3 
Caucasian   23   8.4 
African American   20   7.3 
Other     6   2.2 
Native American     3   1.1 
Asian     1   0.4 
Middle Eastern     1   0.4 
Number of Pregnancies (N = 276) 
Number Frequency Percent 
1 97 35.1 
2 72 26.1 
3 45 16.3 
4 27   9.8 
5 12   4.3 
6   8   2.9 
7   3   1.1 
8   9   3.3 
9   1   0.4 
12   1   0.4 
16   1   0.4 
Number of Previous Live Births (N = 239) 
Number Frequency Percent 
0 72 30.1 
1 68 28.5 
2 50 20.9 
3 23   9.6 
4 10   4.2 
5 10   4.2 
6   3   1.3 
7   1   0.4 
10   1   0.4 
11   1   0.4 
Neonate Gender (N = 225) 
Gender Frequency Percent 
Female 106 47.1 
Male 119 52.9 
 1 
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Table 5  Medical history from pregnant women (PAP = Papanicolaou test; STD = sexually-transmitted disease). 
 
Previous Staphylococcus Infection (N = 278) 
Participant 
ID 
Year Site Treatment Patient History 
99 2008 Abdomen Antibiotics 
 Hashimoto’s disease 
 Surgery in 2006 (cleft lip) 
 Imprisonment in the last year 
 Antibiotic taken in last 6 months 
 Nose/skin/throat problems 
 Abnormal PAP in last year 
277 1999 Arm Antibiotics 
 Has had a family member with kidney failure 
requiring dialysis 
 Antibiotic taken in the last 6 months (self 
and other household member) 
 Chlamydia in the last year 
 Abnormal PAP in the past 
278 1996 Unreported Antibiotics 
 Surgery in 1986 (lymphadenectomy) 
 Surgery in 1998 (C-section) 
 Family member with chronic skin disease 
 Reports working with patients in hospital 
 Circulation problems 
 Antibiotic taken in the last 6 months 
Responses to Having STDs/Abnormal PAP smear (N = 278) 
STD 
Overall Past Year 
Frequency 
Reporting 
Positive 
Percent 
Reporting 
Positive 
Frequency 
Reporting 
Positive 
Percent 
Reporting 
Positive 
Syphilis   1   0.4   0 0.0 
Chlamydia 31 11.2 18 6.5 
Gonorrhea   5   1.8   2 0.7 
Abnormal PAP 39 14.0 28 10.1 
STDs/Abnormal PAP in Medical Record (N = 278) 
STD Frequency Reporting Positive Percent Reporting Positive 
Syphilis 0 0.0 
Chlamydia 6 2.2 
Gonorrhea 2 0.7 
Abnormal PAP 7 2.5 
Comparison of medical record to self report of STDs/Abnormal PAP (N=278) 
 Syphilis was in medical record 0 times, and reported 1 time 
 Gonorrhea was in medical record 2 times and reported 5 times  
 Chlamydia was in medical record 6 times and reported 31 times 
 Abnormal PAPs were in medical record 7 times but were reported 39 times 
 1 
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Table 6  Demographics and characteristics of participants with MRSA positive specimens (Unknown = information 
not provided; N/A = not applicable; N/D = not determined; N = 278). 
 
Participant 
ID 
Who was 
colonized? 
Age 
(yrs.) 
Ethnicity 
Was 
neonate 
also 
colonized 
if mother 
positive? 
Where 
was the 
organism 
isolated? 
Potential risk 
factors or 
medical history 
73 Mother 34.3 Hispanic No Nares 
 Urinary tract, 
bladder or 
kidney 
infections in 
the last year 
 Antibiotic 
use in the last 
6 months 
207 Mother 25.3 Hispanic 
 
N/D 
Vaginal 
 C-section 
delivery with 
this 
pregnancy 
241 Mother Unknown 
African 
American 
No Nares 
 Antibiotic 
use by 
household 
member in 
the last 6 
months 
248 Mother 22.5 Hispanic No Nares 
 Hypertension 
 Household 
member 
hospitalized 
in the last 
year 
 Family 
history of 
skin disease 
 Abnormal 
PAP in the 
last year 
377 Neonate 
 
Newborn 
Unknown N/A Umbilicus 
 Mother 
reports 
urinary tract, 
bladder or 
kidney 
infections in 
the last year 
 1 
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urinary tract, bladder or kidney infections in the 
previous year, antibiotic use in the previous six 
months by the participant or a household member, 
hypertension, hospitalization of household member in 
the previous six months, family history of skin 
disease, and abnormal PAP smear result in the 
previous year (Table 6). 
 
Discussion 
Previous studies of MRSA colonization in pregnant 
women have shown nasal carriage rates ranging from 
1.3 to 2.1%, and vaginal carriage rates ranging from 
0.3 to 1.0% (Beigi & Hanrahan, 2007; James et al., 
2008; Mitsuda, Arai, Fujita, & Yokota, 1996; Reusch 
et al., 2008).  The MRSA colonization prevalence of 
1.0% and 0.3% for nares and vaginal specimens, 
respectively, measured for pregnant women in this 
study is within the range previously observed.  
Studies of MRSA colonization in neonates have 
indicated nasal carriage rates ranging from 0.3 to 
3.9%, and an umbilical carriage rate of 0.7% (James 
et al., 2008; Mitsuda, Arai, Fujita, & Yokota, 1996; 
Reusch et al., 2008).  The MRSA colonization 
prevalence of 0% and 0.6% for nares and umbilicus 
specimens, respectively, measured for neonates in 
this study is consistent with data obtained in a survey 
conducted in 2005–2006 (Reusch et al., 2008).  
Mitsuda et al. obtained a higher MRSA prevalence 
rate in nares (i.e., 3.9%); however, these specimens 
were collected from 6-day-old neonates (Mitsuda, 
Arai, Fujita, & Yokota, 1996) and in the present 
study neonatal specimens were collected at age 1 to 
2-days-old.  Five MRSA positive specimens were 
obtained in this study, and consisted of four from 
pregnant women (i.e., 3 nares, 1 vaginal) and one 
from a neonate (i.e., umbilicus).  While these data did 
not show transmission between MRSA positive 
pregnant women and their newborns, it has been 
suggested that newborn colonization becomes 
apparent 2-3 days or more after birth (Cimolai, 
2003).  Previous studies have demonstrated increased 
MSSA nasal colonization rates over time, for 
newborns, from 3.1% at 1-day-old to 21.9% at 3-
days-old (Cvetniæ, Kuèišec-Tepeš, Šeper, & Šips, 
1991).  Documented MSSA transmission rates 
between pregnant women and their newborns have 
been very low, and vertical transmission of MRSA 
may be <1% (Mitsuda, Arai, Fujita, & Yokota, 1996).  
In some studies, MRSA transmission from pregnant 
women to newborns delivered vaginally was not 
detected (Mitsuda, Arai, Fujita, & Yokota, 1996; 
Reusch et al., 2008). 
 
In pregnant women, MSSA was present in 16.0% of 
the nasal specimens, within the estimates of 6.9 and 
23.0% obtained in previous studies (Beigi & 
Hanrahan, 2007; James et al., 2008; Mitsuda, Arai, 
Fujita, & Yokota, 1996).  Similarly, the MSSA 
vaginal prevalence of 5.2% obtained in this study was 
within the rates of 1.0 and 7.5% previously observed 
(Beigi & Hanrahan, 2007; James et al., 2008; 
Mitsuda, Arai, Fujita, & Yokota, 1996).  In neonates, 
the MSSA colonization prevalence of 0.6% for nares 
specimens was below the range of 3.1 and 10.1% 
obtained in previous surveys (Cvetniæ, Kuèišec-
Tepeš, Šeper, & Šips, 1991; James et al., 2008; 
Mitsuda, Arai, Fujita, & Yokota, 1996).  The higher 
prevalence rate of 10.1% MSSA colonization in nares 
specimens was observed in older neonates (Mitsuda, 
Arai, Fujita, & Yokota, 1996).  The prevalence of 
MSSA in umbilicus specimens in the present study 
was 1.7%; however, no published data are currently 
available for comparison.  In this study, umbilical 
specimens were more likely to detect S. aureus than 
nasal swabs, and there was no transmission observed 
between MSSA positive pregnant women and their 
newborns.  These results are contrary to those 
obtained by Mitsuda et al. who saw a greater 
sensitivity in nasal specimens compared to umbilicus 
swabs, and a 1.3% (4/305) MSSA transmission rate 
from mother to infant (Mitsuda, Arai, Fujita, & 
Yokota, 1996).  It is possible that the collection of 
specimens at 6-days of age may be related to the 
colonization sites and rates observed by Mitsuda et 
al. (Mitsuda, Arai, Fujita, & Yokota, 1996). 
 
Results obtained with the Kirby-Bauer disc diffusion 
method were equivalent to data obtained with the 
VITEK 2 Compact, with the exception that isolates 
that showed intermediate levofloxacin resistance with 
the VITEK 2 Compact were determined to be 
resistant with the Kirby-Bauer method.  The reasons 
for the discrepancy are unknown. 
 
MRSA infections that are acquired by persons who 
have not been recently hospitalized or have had a 
medical procedure are termed CA-MRSA infections.  
On the basis of questionnaire data, 4 of the 5 isolates 
in this study appear to be CA-MRSA.  Strain typing 
using the bioMérieux DiversiLab
®
 System database 
indicated that the 3 isolates with identical 
antimicrobial agent susceptibility profiles were most 
closely related to the Iberian MRSA strain.  While 
the DiversiLab is useful for screening MRSA 
isolates, pulsed-field gel electrophoresis (PFGE) may 
be necessary for confirming specific USA types 
(Ross, Merz, Farkosh, & Carroll, 2005; Tenover et 
al., 2009).  The participants in this study were 
representative of the pregnant women delivering 
vaginally at this university-affiliated clinic.  From the 
questionnaire data, no statistically significant factors 
could be identified for MRSA colonization among 
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the pregnant women.  This is in part due to the low 
colonization rates that provided very limited 
statistical power to evaluate risk factors.  These low 
carriage rates have been observed in similar studies 
of vertical transmission (Reusch et al., 2008). 
 
This is the first known survey of MRSA colonization 
of healthy neonates and pregnant women in Las 
Vegas, and the results will be useful in establishing a 
baseline to determine future increases in MRSA 
colonization rates among this population.  It is 
expected that strain characterization of the MRSA 
positive isolates will help in developing 
recommendations for selecting antimicrobial therapy, 
and is the first step in establishing a pediatric 
database of the antimicrobial susceptibility of 
infection-causing microorganisms for all Las Vegas, 
Nevada hospitals. 
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